drugset
drugset / Trial / NCT00087204

Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

NCT00087204 ↗

Phase 1 Completed 40 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of rebeccamycin analog in treating patients with relapsed or refractory acute myeloid leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, or chronic myelogenous leukemia in blast phase. Drugs used in chemotherapy, such as rebeccamycin analog, work in different ways to stop cancer cells from dividing so they stop growing or die

Timeline

Start
2004-05
Primary completion
2007-01
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject becatecarin Other / unclassified — Intravenous

Indications

acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(16;16)(p13.1;q22) adult acute lymphoblastic leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive chronic myelomonocytic leukemia myelodysplastic syndrome with excess blasts refractory anemia with excess blasts in transformation